Versant Ventures has launched Granite Bio with $100 million in funding, advancing two novel antibody drugs targeting inflammatory conditions through its Ridgeline Therapeutics initiative.
Halia Therapeutics has been awarded the Novo Nordisk Golden Ticket, providing fully sponsored BioLabs space and mentorship to advance their research on chronic inflammation and obesity-related diseases.
Halia Therapeutics' CEO, Dr. David J. Bearss, will participate in a panel at the BIO Investor Forum on October 15, 2024, focusing on neurodegenerative disease targets.